Do GLP-1 receptor agonists reduce major limb events for patients with Peripheral Artery Disease?
Peripheral artery disease (PAD) narrows leg arteries, raising the risk of limb complications like amputation. GLP-1 receptor agonists (GLP-1 RAs), originally diabetes drugs, also protect the heart and blood vessels. For people with type 2 diabetes and PAD, research shows these medications lower the chance of major limb events — serious problems such as amputation or surgery to restore blood flow.
What the research says
A 2026 systematic review and meta-analysis of 12 studies (2 randomized trials and 10 large cohort studies) including over 418,000 participants with type 2 diabetes and PAD found that GLP-1 RA treatment was linked to a 27% lower risk of major limb events (a composite of amputation, revascularization, and gangrene) 11. Specifically, the risk of lower extremity amputation fell by 24%, revascularization by 19%, and gangrene by 20% 11. These benefits appeared consistent across different patient groups and study designs 11.
Another 2026 meta-analysis of 6 randomized trials with 7,645 participants with diabetes and PAD confirmed that GLP-1 RAs reduced major adverse cardiovascular events (MACE) by 14% and all-cause death by 17%, but did not find a statistically significant reduction in major adverse limb events (MALE) on its own 10. The difference may be because this smaller analysis had fewer limb events to analyze 1011.
A 2024 review of medical therapy for PAD also lists GLP-1 RAs among glucose-lowering drugs that show benefits for both cardiovascular and limb outcomes, though it notes that use of these therapies in PAD patients remains low in practice 9. The cardiovascular benefits of GLP-1 RAs are thought to come from direct effects on blood vessel lining, reduced inflammation, and improvements in weight and blood pressure 2.
What to ask your doctor
- Based on my PAD and diabetes, could a GLP-1 receptor agonist help lower my risk of limb complications?
- What are the potential side effects of GLP-1 RAs, and how do they compare with other medications I take?
- Are there any interactions between GLP-1 RAs and my current blood thinners or cholesterol medications?
- How should I monitor for symptoms of PAD worsening while on this medication?
- Is there a specific GLP-1 RA that has the best evidence for PAD outcomes?
This question is drawn from common patient questions about Cardiology and answered using cited medical research. We do not provide individualized advice.